| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Oncologic safety and reproductive outcomes of conservative therapy for early-stage endometrial disease
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Aisha Jamil, Ghulam Sughra, Ghazala Dawood Abbasi, Soukaina Adane, Monica Punshi, Mobashara Ghulam Muhammad, Marium Nausherwan, Yamina Ishtiaq and Muhammad Dawood Hazoor |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Muhammad Dawood Hazoor, MD, Department of Internal Medicine, International University of Kyrgyzstan, ISM IUK Eastern Campus, Bishkek, Kyrgyzstan, 6 Seven April Street, Bishkek 750065, Kyrgyzstan. sidhudawood@gmail.com |
| Key Words |
Endometrial cancer; Atypical hyperplasia; Fertility-sparing management; Progestin therapy; Biomarkers; Ki-67; Human epididymis protein 4; Molecular classification; Reproductive outcomes; Oncologic safety |
| Core Tip |
This multicenter retrospective study of 234 women with atypical hyperplasia or early-stage endometrial cancer demonstrates fertility-sparing management’s efficacy, with 79.9% complete response, 25.1% recurrence, and 50.4% live birth rate. Innovatively, biomarkers (Ki-67 > 20%, human epididymis protein 4 > 50 pmol/L) independently predict recurrence (hazard ratios = 3.12 and 2.78), while molecular classification (e.g., no specific molecular profile favorable) refines patient selection, advocating multidisciplinary approaches for optimized oncologic and reproductive outcomes. |
| Publish Date |
2026-03-23 08:21 |
| Citation |
Jamil A, Sughra G, Abbasi GD, Adane S, Punshi M, Muhammad MG, Nausherwan M, Ishtiaq Y, Hazoor MD. Oncologic safety and reproductive outcomes of conservative therapy for early-stage endometrial disease. World J Clin Oncol 2026; 17(3): 116062 |
| URL |
https://www.wjgnet.com/2218-4333/full/v17/i3/116062.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v17.i3.116062 |
